Boehringer Ingelheim and MD Anderson form collaboration

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies  New potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim ’s innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson The Center will initially investigate KRAS pathway inhibitors and a TRAILR2 antibody from Boehringer Ingelheim ’s cancer research  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news